Teclistamab for Relapsed/Refractory Multiple Myeloma: Real-World Experience in an Early Access Program

Uttervall, Katarina; Nahi, Hareth; Kashif, Muhammad; Lemonakis, Konstantinos; Rosengren, Sara; Brolin, Janaki; Lund, Johan; Hansson, Markus

doi:10.1182/blood-2022-158801

Cited by 6 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, a Swedish real‐world experience of using Teclistamab‐cqyv in an early access program 51 demonstrated that the drug is effective with acceptable side effects, which is consistent with the findings of a pivotal study. Indeed, approximately 41% of patients were penta‐drug refractory and 88% had previously received ASCT.…”

Section: Future Perspectivesupporting

confidence: 78%

Teclistamab‐cqyv in multiple myeloma

Martino,

Bruzzese,

Labanca

et al. 2023

European J of Haematology

View full text Add to dashboard Cite

Multiple myeloma (MM) is an incurable neoplasm characterized by significant morbidity and mortality. Despite advances in treatment, MM patients eventually experienced a relapse of the disease. Penta‐drug refractory patients continue to be the hard core of relapsed/refractory (RR) settings. Teclistamab‐cqyv is a humanized IgG4 antibody and a bispecific BCMA‐director CD3 T‐cell engager. It recruits endogenous T cells, by targeting CD3 receptors expressed on their surface, resulting in their activation against BCMA, an antigen expressed by plasma cells. US Food and Drug Administration (FDA) and European Medicines Agency (EMA) have approved Teclistamab‐cqyv in monotherapy for the treatment of RRMM patients who have received at least three prior therapies, including immunomodulatory drugs (IMiDs), proteasome inhibitors (PIs), and anti‐CD38 monoclonal antibodies (MoAbs) and have demonstrated disease progression during the last therapy. Its effectiveness was demonstrated in a pivotal clinical trial where the overall response rate (ORR) reached 60%. Other clinical studies are currently ongoing to investigate the association of the bispecific antibody with novel drugs with encouraging preliminary results, especially in the setting of heavily pretreated patients. In this review, the authors will provide a comprehensive overview of the drug, including its mechanism of action, major clinical trials, and future perspectives.

show abstract

Section: Future Perspectivesupporting

confidence: 78%

Teclistamab‐cqyv in multiple myeloma

Martino,

Bruzzese,

Labanca

et al. 2023

European J of Haematology

View full text Add to dashboard Cite

show abstract

“…Whereas, regarding blenrep, 21% developed anemia and 19% thrombocytopenia in the 2.5 mg/kg cohort, and 28% anemia and 29% thrombocytopenia in the 3.4 mg/kg cohort [18]. From real-world experience, anemia was seen in 100% of patients (88% G ≥ 3), neutropenia in 100% (100% G ≥ 3), thrombocytopenia in 94% (75% G ≥ 3), febrile neutropenia in 69% after ide-cel (n = 16) administration; anemia in 25.8% (10.9% G ≥ 3), thrombocytopenia in 23% (17.7% G ≥ 3), neutropenia in 15.7% (13.3% G ≥ 3) after cilta-cel; neutropenic fever in 6% following teclistamab (n = 17); thrombocytopenia in 27.4% (17.9% G ≥ 3), anemia in 11.3% (3.8% G ≥ 3), and neutropenia in 7.5% (4.7% G ≥ 3) following blenrep (n = 106) therapy [40][41][42][43].…”

Section: Cytopenia(s)mentioning

confidence: 99%

“…The incidence of overall infection was recorded at 78%, with respiratory infections at 56%, COVID-19 in 27%, other viral in 10%, fungal in 5%, pneumocystis in 4%, and hepatitis B in 0.6% of patients [17]. From real-world experience, infection was seen in 31%, 28.6%, 35%, and 1.9% of patients following ide-cel, cilta-cel, teclistamab, and blenrep administration, respectively [40][41][42][43].…”

Section: Infectionmentioning

confidence: 99%

See 1 more Smart Citation

Management of Adverse Reactions for BCMA-Directed Therapy in Relapsed Multiple Myeloma: A Focused Review

Khanam,

Faiman,

Batool

et al. 2023

JCM

View full text Add to dashboard Cite

Anti-B-cell maturation antigen therapies consisting of bispecific antibodies, antibody–drug conjugates, and chimeric antigen receptor T cells have shown promising results in relapsed refractory multiple myeloma (RRMM). However, the severe side effects include cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, cytopenia(s), infections, hemophagocytic lymphohistiocytosis, and organ toxicity, which could sometimes be life-threatening. This review focuses on these most common complications post-BCMA therapy. We discussed the risk factors, pathogenesis, clinical features associated with these complications, and how to prevent and treat them. We included four original studies for this focused review. All four agents (idecabtagene vicleucel, ciltacabtagene autoleucel, teclistamab, belantamab mafodotin) have received FDA approval for adult RRMM patients. We went through the FDA access data packages of the approved agents to outline stepwise management of the complications for better patient outcomes.

show abstract

“…Teclistamab, a BsAb targeting B-cell maturation antigen (BCMA)/CD3, is currently the most advanced in clinical development, having been approved by the FDA and European Medicines Agency (EMA) in 2022 for the treatment of heavily pretreated MM patients. In a phase I–II study, 1 17 patients (88% triple-class refractory) received teclistamab at dose of 1500 µg/kg every weekly (QW) ( n = 15) or every 2 weeks (Q2W) ( n = 2) ( Abstract 158801 ). At data cutoff, 15 patients were evaluable, and the ORR was 60%, with 53% achieving very good partial response (VGPR) or better.…”

Section: Bcma × Cd3mentioning

confidence: 99%

Bispecific antibody treatment of multiple myeloma: latest updates from the 2022 ASH annual meeting

Yin,

Liu,

Sun

et al. 2023

Therapeutic Advances in Chronic Disease

View full text Add to dashboard Cite

Background: Effective novel therapies for multiple myeloma (MM) patients who are unresponsive to conventional treatments (triple-class refractory) are an urgent need. Bispecific antibodies (BsAbs) offer a promising new approach to stimulate T cells and induce tumor cell death by targeting molecules on the surface of malignant plasma cells and CD3 on the surface of T cells. Objectives: Addressing the issue of improving the prognosis of triple-class refractory MM patients has become a significant clinical challenge. Design: This is a brief report. Methods: This article summarizes the latest updates of BsAbs treatment of MM from the 2022 ASH annual meeting. Results: BsAbs that target B-cell maturation antigen and G protein-coupled receptor family C group 5 memberD have demonstrated remarkable clinical activity and favorable safety profiles. Many potential targets for myeloma cells are currently undergoing phase I/II clinical trials, and these off-the-shelf bispecific molecules are likely to become a critical part of the MM treatment landscape. Conclusion: This article provides an overview of the latest advances in BsAbs immunotherapy for refractory and relapsed MM and highlights significant findings from the 2022 ASH annual meeting.

show abstract

Teclistamab for Relapsed/Refractory Multiple Myeloma: Real-World Experience in an Early Access Program

Cited by 6 publications

References 0 publications

Teclistamab‐cqyv in multiple myeloma

Teclistamab‐cqyv in multiple myeloma

Management of Adverse Reactions for BCMA-Directed Therapy in Relapsed Multiple Myeloma: A Focused Review

Bispecific antibody treatment of multiple myeloma: latest updates from the 2022 ASH annual meeting

Contact Info

Product

Resources

About